Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain study).


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 26 03 2020
revised: 07 08 2020
accepted: 02 09 2020
pubmed: 26 9 2020
medline: 20 7 2021
entrez: 25 9 2020
Statut: ppublish

Résumé

Experimental evidence indicates that exercise performed at different times of the day may affect circadian rhythms and circadian disruption has been linked to breast and prostate cancer. We examined in a population-based case-control study (MCC-Spain) if the time-of-day when physical activity is done affects prostate and breast cancer risk. Lifetime recreational and household physical activity was assessed by in-person interviews. Information on time-of-day of activity (assessed approximately 3 years after the assessment of lifetime physical activity and confounders) was available for 781 breast cancer cases, 865 population female controls, 504 prostate cases and 645 population male controls from 10 Spanish regions, 2008-2013. We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for different activity timings compared to inactive subjects using unconditional logistic regression adjusting for confounders. Early morning (8-10 am) activity was associated with a protective effect compared to no physical activity for both breast (OR = 0.74, 95% CI = 0.48-1.15) and prostate cancer (OR = 0.73, 95% CI = 0.44-1.20); meta-OR for the two cancers combined 0.74 (95%CI = 0.53-1.02). There was no effect observed for breast or prostate cancer for late morning to afternoon activity while a protective effect was also observed for evening activity only for prostate cancer (OR = 0.75, 95% CI = 0.45-1.24). Protective effects of early morning activity were more pronounced for intermediate/evening chronotypes for both cancers. This is the first population-based investigation identifying a differential effect of timing of physical activity on cancer risk with more pronounced effects for morning hour activity. Our results, if confirmed, may improve current physical activity recommendations for cancer prevention.

Identifiants

pubmed: 32976649
doi: 10.1002/ijc.33310
pmc: PMC7891656
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1360-1371

Informations de copyright

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.

Références

Sleep Med. 2017 Jun;34:200-208
pubmed: 28522092
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Trends Cancer. 2019 Aug;5(8):475-494
pubmed: 31421905
Ann Oncol. 2018 May 1;29(5):1154-1179
pubmed: 29788165
Breast Cancer. 2017 Jan;24(1):42-51
pubmed: 27017208
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Br J Cancer. 2001 Sep 28;85(7):962-5
pubmed: 11592766
Am J Epidemiol. 2004 Apr 15;159(8):740-9
pubmed: 15051583
Transl Oncol. 2018 Apr;11(2):275-285
pubmed: 29413760
Front Biosci (Landmark Ed). 2012 Jun 01;17(7):2433-41
pubmed: 22652790
Am J Epidemiol. 2001 Aug 15;154(4):336-47
pubmed: 11495857
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):985-991
pubmed: 28377415
Br J Sports Med. 2018 Jul;52(13):826-833
pubmed: 29146752
Int J Cancer. 2018 Nov 15;143(10):2380-2389
pubmed: 30016830
Eur J Appl Physiol. 2009 Apr;105(6):823-8
pubmed: 19205725
Molecules. 2018 Feb 26;23(3):
pubmed: 29495398
Int J Cancer. 2021 Mar 15;148(6):1360-1371
pubmed: 32976649
Br J Sports Med. 2016 Mar;50(6):339-45
pubmed: 26385207
Int J Obes (Lond). 2020 Jan;44(1):114-124
pubmed: 31289334
J Phys Act Health. 2016 Apr;13(4):416-8
pubmed: 26445277
Lancet Oncol. 2019 Aug;20(8):1058-1059
pubmed: 31281097
Clin Obes. 2017 Jun;7(3):157-165
pubmed: 28343364
Environ Health Perspect. 2018 Apr 23;126(4):047011
pubmed: 29687979
Immunol Cell Biol. 2014 Apr;92(4):331-9
pubmed: 24751614
Nat Sci Sleep. 2009 Nov 04;1:1-8
pubmed: 23616692
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):854-63
pubmed: 25737330
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Chronobiol Int. 2014 Mar;31(2):276-82
pubmed: 24517176
Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii43-ii50
pubmed: 29982781
J Physiol. 2019 Apr;597(8):2253-2268
pubmed: 30784068
Int J Epidemiol. 1993 Jun;22(3):512-9
pubmed: 8359969
Br J Sports Med. 2008 Aug;42(8):636-47
pubmed: 18487249
Chronobiol Int. 2017;34(2):203-211
pubmed: 27996309
Sleep Med Rev. 2007 Dec;11(6):429-38
pubmed: 17936039
Breast Cancer Res. 2015 Nov 05;17(1):139
pubmed: 26541144
Curr Opin Oncol. 2015 Jan;27(1):50-6
pubmed: 25405464
Clin Breast Cancer. 2018 Aug;18(4):e601-e612
pubmed: 29223719
Lancet Oncol. 2013 Sep;14(10):1009-19
pubmed: 23890780
J Pineal Res. 2003 Jan;34(1):11-6
pubmed: 12485366
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
PLoS One. 2015 Sep 09;10(9):e0137567
pubmed: 26352938
Int J Cancer. 2018 Nov 15;143(10):2369-2379
pubmed: 29744870
Am J Physiol Regul Integr Comp Physiol. 2015 Nov 1;309(9):R1112-21
pubmed: 26333783
Curr Environ Health Rep. 2017 Sep;4(3):325-339
pubmed: 28770538
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
Eur J Endocrinol. 2003 Feb;148(2):227-32
pubmed: 12590642

Auteurs

Jakob Weitzer (J)

Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.

Gemma Castaño-Vinyals (G)

Universitat Pompeu Fabra (UPF), Barcelona, Spain.
ISGlobal, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Nuria Aragonés (N)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Public Health Division, Department of Health, Epidemiology Section, Madrid, Spain.

Inés Gómez-Acebo (I)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Universidad de Cantabria-IDIVAL, Santander, Spain.

Marcela Guevara (M)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Pilar Amiano (P)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Ministry of Health of the Basque Government, Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Donostia-San Sebastian, Spain.

Vicente Martín (V)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, León, Spain.
Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, León, Spain.

Ana Molina-Barceló (A)

Cancer and Public Health Area, FISABIO-Public Health, Valencia, Spain.

Juan Alguacil (J)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Environmental Epidemiology and Neuroscience Laboratory, RENSMA, Huelva University, Huelva, Spain.

Victor Moreno (V)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Cancer Epidemiology Research Program, IDIBELL, Hospitalet de Llobregat, Spain.
Catalan Institute of Oncology, Hospitalet de Llobregat, Spain.
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Claudia Suarez-Calleja (C)

IUOPA, University of Oviedo and ISPA, Oviedo, Spain.

José Juan Jiménez-Moleón (JJ)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Department of Preventive Medicine and Public Health, School of Medicine, University of Granada & Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain.

Rafael Marcos-Gragera (R)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain.
Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director d'Oncologia, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona (IdIBGi), Universitat de Girona, Girona, Spain.

Kyriaki Papantoniou (K)

Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.

Beatriz Pérez-Gómez (B)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Cardiovascular & Metabolic Diseases Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

Javier Llorca (J)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Universidad de Cantabria-IDIVAL, Santander, Spain.

Nieves Ascunce (N)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Leire Gil (L)

Ministry of Health of the Basque Government, Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Donostia-San Sebastian, Spain.

Esther Gracia-Lavedan (E)

ISGlobal, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.

Delphine Casabonne (D)

Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Hospitalet de Llobregat, Spain.
Cancer Epidemiology Research Program, IDIBELL, Hospitalet de Llobregat, Spain.
Catalan Institute of Oncology, Hospitalet de Llobregat, Spain.

Virginia Lope (V)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Marina Pollán (M)

CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.

Manolis Kogevinas (M)

Universitat Pompeu Fabra (UPF), Barcelona, Spain.
ISGlobal, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH